Kura Oncology (Nasdaq:KURA) - Stock Price, News & Analysis

KURA Stock Overview

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.

KURA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 11.9% below our estimate of its fair value

Analysts in good agreement that stock price will rise by 59.2%

Risk Analysis

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Significant insider selling over the past 3 months

Kura Oncology, Inc. Competitors

Arcus Biosciences

NYSE:RCUS

US$1.3b

Veracyte

NasdaqGM:VCYT

US$1.5b

Akero Therapeutics

NasdaqGS:AKRO

US$1.3b

Morphic Holding

NasdaqGM:MORF

US$1.4b

Price History & Performance

Summary of all time highs, changes and price drops for Kura Oncology
Historical stock prices
Current Share Price	US$19.00
52 Week High	US$24.17
52 Week Low	US$7.41
Beta	0.87
1 Month Change	-6.95%
3 Month Change	5.67%
1 Year Change	97.51%
3 Year Change	-30.88%
5 Year Change	26.25%
Change since IPO	26.67%

Kura Oncology: Ziftomenib's Path To AML Market Widens

Jan 31

Recent updates

Kura Oncology: Ziftomenib's Path To AML Market Widens

Jan 31

Kura Oncology, Inc.'s (NASDAQ:KURA) Intrinsic Value Is Potentially 72% Above Its Share Price

Jan 25

Is Kura Oncology (NASDAQ:KURA) A Risky Investment?

Aug 14

Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?

Apr 04

Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 44% Undervaluation?

Jan 31

Kura Oncology (NASDAQ:KURA) Is In A Good Position To Deliver On Growth Plans

Oct 10

Kura Oncology stock rises 7% as Cantor Fitzgerald begins coverage with Overweight rating

Jul 13

What Kind Of Shareholders Hold The Majority In Kura Oncology, Inc.'s (NASDAQ:KURA) Shares?

Dec 14

Kura Oncology: Advanced Precision Medicine Opportunity Excites, But Not Without Risks

Dec 10

Kura Oncology (KURA) Presents At ASH Virtual Investor Event

Dec 08

Kura Oncology Jumps 16% After Announcing First In-Human Data for AML Candidate

Dec 07

Kura Oncology (KURA) Presents At Stifel Healthcare Conference - Slideshow

Nov 17

Shareholder Returns

	KURA	US Biotechs	US Market
7D	7.5%	0.4%	1.0%
1Y	97.5%	0.9%	21.9%

Return vs Industry: KURA exceeded the US Biotechs industry which returned 0.7% over the past year.

Return vs Market: KURA exceeded the US Market which returned 24.9% over the past year.

Price Volatility

Is KURA's price volatile compared to industry and market?
KURA volatility
KURA Average Weekly Movement	7.4%
Biotechs Industry Average Movement	11.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.0%

Stable Share Price: KURA's share price has been volatile over the past 3 months.

Volatility Over Time: KURA's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2014	142	Troy Wilson	kuraoncology.com

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

Kura Oncology, Inc. Fundamentals Summary

How do Kura Oncology's earnings and revenue compare to its market cap?
KURA fundamental statistics
Market cap	US$1.45b
Earnings (TTM)	-US$152.63m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-9.5x

P/E Ratio

Is KURA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KURA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$152.63m
Earnings	-US$152.63m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 02, 2024

Earnings per share (EPS)	-2.00
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	2.3%

How did KURA perform over the long term?

See historical performance and comparison

KURA Stock Overview

Rewards

Risk Analysis

Kura Oncology, Inc. Competitors

NYSE:RCUS

US$1.3b

NasdaqGM:VCYT

US$1.5b

NasdaqGS:AKRO

US$1.3b

NasdaqGM:MORF

US$1.4b

Price History & Performance

Recent News & Updates

Kura Oncology, Inc. Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

Kura Oncology, Inc., Annual General Meeting, Jun 05, 2024

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

Kura Oncology, Inc. Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

Kura Oncology, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Kura Oncology: Ziftomenib's Path To AML Market Widens

Recent updates

Kura Oncology, Inc. Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

Kura Oncology, Inc., Annual General Meeting, Jun 05, 2024

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

Kura Oncology, Inc. Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

Kura Oncology, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Kura Oncology: Ziftomenib's Path To AML Market Widens

Kura Oncology, Inc. Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

Chairman notifies of intention to sell stock

Kura Oncology, Inc.'s (NASDAQ:KURA) Intrinsic Value Is Potentially 72% Above Its Share Price

New minor risk - Share price stability

Kura Oncology, Inc. announced that it expects to receive $150 million in funding from EcoR1 Capital, LLC

Price target decreased by 10% to US$28.46

Kura Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Kura Oncology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Kura Oncology, Inc. Announces First Patient Dosed in Fit-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASG12C Inhibitors in Non-Small Cell Lung Cancer

Kura Oncology Appoints Brian Powl as Chief Commercial Officer

Is Kura Oncology (NASDAQ:KURA) A Risky Investment?

Kura Oncology, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Kura Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $99.999707 million.

Kura Oncology, Inc. Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib At 2023 European Hematology Association Congress

Kura Oncology, Inc. to Report Q1, 2023 Results on May 10, 2023

Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?

Kura Oncology, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Kura Oncology, Inc. Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia

Chief Medical Officer recently sold US$61k worth of stock

Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 44% Undervaluation?

Kura Oncology Announces FDA Clearance of IND Application for KO-2806, A Next-Generation Farnesyl Transferase Inhibitor

Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib

Kura Oncology, Inc. announced that it expects to receive $150.000003 million in funding from Bristol-Myers Squibb Company,

Kura Oncology, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Kura Oncology, Inc. Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma

Kura Oncology (NASDAQ:KURA) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$32.67

Kura Oncology, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Kura Oncology stock rises 7% as Cantor Fitzgerald begins coverage with Overweight rating

We Think Kura Oncology (NASDAQ:KURA) Can Afford To Drive Business Growth

Kura Oncology, Inc. Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer

Kura Oncology, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Kura Oncology, Inc. Announces Executive Changes

Kura Oncology, Inc. Announces Executive Changes

Kura Oncology, Inc. Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Kura Oncology, Inc. Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

Kura Oncology, Inc. Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma

Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Price target decreased to US$38.43

We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

Insider notifies of intention to sell stock

We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

Independent Director Robert Hoffman has left the company

Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell 3000E Index

Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539

Kura Oncology Investor Presentation - Slideshow

Price target decreased to US$41.63

Chief Operating Officer exercised options and sold US$63k worth of stock

Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma

New 90-day low: US$29.15

Kura Oncology, Inc. to Report Q4, 2020 Results on Feb 24, 2021

New 90-day low: US$29.73